pegsiticase
Recombinant proteinexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT01021241)
Timeline
Indications
Studied for
Mechanism of action
- Dual oxidase 1Supplementation
DUOX1 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pegsiticase
- pegsiticase
- uricase-peg 20
- uricase-peg 20
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02959918 | Phase 2 | Oct 1, 2016 | Selecta Biosciences, Inc. |
| NCT02648269 | Phase 1 | Dec 1, 2015 | Selecta Biosciences, Inc. |
| NCT02464605 | Phase 1 | May 1, 2015 | Selecta Biosciences, Inc. |
| NCT01038947 | Phase 1 | Dec 1, 2009 | EnzymeRx, MRA Clinical Research |
| NCT01021241 | Phase 1 | Oct 1, 2009 | Altoona Center for Clinical Research, EnzymeRx |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Selecta Biosciences, Inc. | For profit | 3 | 3 | 2 | 2015 |
| EnzymeRx | For profit | 2 | 2 | 1 | 2009 |
| Altoona Center for Clinical Research | For profit | 1 | 0 | 1 | 2009 |
| MRA Clinical Research | Academic/Hospital | 1 | 0 | 1 | 2009 |
4 organizations
Page 1 / 1